IPHARMA is a well-established CRO that manages clinical trials in Russia and EAEU. Clinical branch of ChemRar group, and partner of Skolkovo Innovative center.

About us

IPHARMA contract research organization was established as the part of ChemRar High-Tech Center in order to realize the full cycle clinical development of innovative drugs. The company was headed by a team of specialists with an extensive experience in conducting international and local clinical trials.

IPHARMA became a sub-contractor for 10 state contracts in the transfer of international drugs, organization and conduct of clinical trials of innovative drugs.

 

IPHARMA obtained 11 Clinical trial authorizations issued by the Ministry of Health for the conduct of the clinical trials on diabetes mellitus, schizophrenia, hepatitis C, melanoma, lung cancer, ovarian cancer and the prevention of thromboembolic complications in orthopedics.  

 

Based on the newsletter issued by Association of Clinical Trial Organizations (ACTO), IPHARMA keeps the leadership in the number of clinical trials of Russian innovative drugs.

IPHARMA got the status of a common use center of "Skolkovo".

 

IPHARMA obtained 6 Clinical trial authorizations issued by the Ministry of Health for conduct of the clinical trials on HIV, hepatitis C, liver transplantation, prostate cancer, non-Hodgkin's lymphoma, kidney cancer, and bronchial asthma.  

IPHARMA implemented the training program for young clinical trial specialists.

 

Presentations at the conferences "Current issues of pre-clinical and clinical trials of drugs and medical devices" (Saint Petersburg) and "Clinical trials in Russia" (Moscow, Adam Smith Institute).

 

Based on newsletter issued by Association of Clinical Trial Organizations (ACTO), IPHARMA keeps the leadership in the number of clinical trials of Russian innovative drugs.

IPHARMA obtained 13 Clinical trial authorizations issued by the Ministry of Health for conduct of the clinical trials on influenza, rheumatoid arthritis, hepatitis B, hepatitis C, Meniere's disease, ovarian cancer and bronchial asthma.

Opening of a new IPHARMA office at "Skolkovo" Technopark.

Presentations at international conferences: 75th Scientific Sessions ADA, Boston, MA and 51st Annual Meeting DIA, Washington, DC and "Clinical trials in Russia", Adam Smith Institute, Moscow.

 

Based on newsletter issued by Association of Clinical Trial Organizations (ACTO), IPHARMA keeps the leadership in the number of clinical trials of Russian innovative drugs.

IPHARMA obtained 22 Clinical trial authorizations issued by the Ministry of Health for conduct of the clinical trials on diabetes mellitus, cough, hepatitis C, breast cancer, lung cancer, Meniere's disease, metabolic syndrome and acute respiratory viral infection.

Launch of the Pharmacovigilance system for investigational drugs. Seminars in the frame of educational program Pharma’s cool of Skolkovo Open University.

 

Scientific co-operation agreement with First Moscow State Medical University n.a. I.M. Sechenov. Presentations at international conferences: 28th Annual DIA EuroMeeting, Hamburg, Germany, and 52nd Annual Meeting DIA, Philadelphia, PA and "Clinical trials in Russia", Adam Smith Institute, Moscow..

 

Participation in international co-operation programs (Czech Republic, Cuba). Innovative drugs Gozogliptin and Normacore investigated by IPHARMA obtained marketing authorizations.  

Based on newsletter issued by Association of Clinical Trial Organizations (ACTO), IPHARMA keeps the leadership in the number of clinical trials of Russian innovative drugs.

IPHARMA obtained 15 authorizations issued by the Ministry of Health of the Russian Federation. According to the ACTO Newsletter, the summary of 2017 results showed that IPHARMA topped the list of local CROs.

Participating in international and local conferences and programs: GeneratonS, DIA 2017 Annual Meeting, 6th International Forum "Clinical Research in Russia", III All-Russian Endocrinological Congress, etc.

Conducting seminars within the educational programs “Pharma’s cool” of the Open University Skolkovo, the “Development of Innovative Medicines” of the Skolkovo Foundation's Biomedical cluster, the Department for Industrial Pharmacy of the Pharmaceutical Faculty of the I.M. Sechenov First Moscow State Medical University.  

Organizing and holding of the Social and pharmaceutical Forum "Patient as a partner: Drug development, clinical studies and innovative treatment methods" and the first face-to-face meeting of the Clinical Trial Quality Assurance Forum.

IPHARMA obtained 7 authorizations issued by the Ministry of Health of the Russian Federation. According to the ACTO Newsletter, the summary of 2018 results showed that IPHARMA topped the list of local CROs.

 

​Launching two new services: registration of medicinal products and medical devices, data processing and biostatistics.

Participation in international and local conferences of the DIA, Adam Smith Institute, Skolkovo Foundation.

Launching www.ClinLine.ru – the first platform for interaction between patients, investigators and organizers of clinical trials in Russia. The platform was developed within the framework of the Neuronet roadmap of the National Technology Initiative with the support of the Fund for Assistance to Small Innovative Enterprises in Science and Technology.

IPHARMA obtained 11 authorizations issued by the Ministry of Health of the Russian Federation.

Participation in international and local conferences of the DIA, Adam Smith Institute, Skolkovo Foundation. Representation of the Russian clinical trial market in China (PuE Business Mission in Pharma) and Japan (KOBE Biomedical Innovation Cluster).

The iDossier program for preparation of registration dossiers in the eCTD format in accordance with the EAEU requirements is developed.

Launching the ProDrug mobile app to search for medicinal products and their analogues, as well as for the efficacy data, contraindications, etc. Available on the Google Play.

Training students under the educational programs “Pharma’s cool” of the Open University Skolkovo and StudStock of the MIPT.

IPHARMA obtained 16 authorizations issued by the Ministry of Health of the Russian Federation. According to 2020 results, IPHARMA entered the TOP-3 list of Russian CROs.

 

Starting 10 clinical trials of candidate drugs for COVID-19 treatment and prophylaxis, including the clinical trial of Gam-COVID-Vac vaccine in the Republic of Belarus with over 1000 patients enrolled.

Three original medicinal products have been registered, including the vaccine in the Republic of Belarus, along with 14 medical devices - PCR tests and immunochromatographic antibody rapid tests to detect specific antigens of SARS-CoV-2.

New service introduced – a package insert user testing.

 

​Participation in international and local conferences: “Pharma Week” in the EAEU 2020, VI St. Petersburg International Oncological Forum “White Nights” and “Clinical Trials in Russia”  Adam Smith Forums.

The training on "Biostatistics in Clinical Research" for the 5th course of the MIPT Department of Innovative Pharmaceutics, Medical Equipment and Biotechnology has been conducted.